Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of metastatic breast cancer that has progressed on or failed at least one salvage chemotherapy regimen for metastatic disease and that meets the following disease specific related criteria:~  * Measureable metastatic disease per Response Evaluation Criteria In Solid Tumor (RECIST) - bone only not eligible.~ * Disease progression while receiving prior therapy with a hormonal agent (if estrogen/progesterone receptor-positive) and/or trastuzumab (Herceptin®) (if HER2-neu positive)~ * Brain metastases allowed provided they are stable for ≥ 3 months after prior treatment~* Related HLA-haploidentical natural killer cell donor available (by ≥ class I serologic typing)~* Male or female~* Performance status 50-100%~* Platelet count ≥ 80,000/mm³ (unsupported by transfusions)~* Hemoglobin ≥ 9 g/dL (unsupported by transfusions)~* Absolute neutrophil count ≥ 1,000/mm³ (unsupported by sargramostim \[GM-CSF\] or filgrastim \[G-CSF\])~* Creatinine ≤ 2.0 mg/dL~* Liver function tests \< 5 times normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* LVEF \> 40%\*~* Pulmonary function \> 50%\* (DLCO corrected AND FEV_1)~* No active infection (i.e., afebrile, off antibiotics, and no uninvestigated radiologic lesions)~Exclusion Criteria:~* At least 3 days since prior prednisone or other immunosuppressive medications~* No other concurrent therapy for cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Treated Patients (Type: EXPERIMENTAL): All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).